Dr. Ashley Elimar Aaroe, MD

Dr. Aaroe practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Aaroe's NPI, 1902295793, was assigned on January 15, 2015. Dr. Aaroe graduated from Feinberg School of Medicine in 2015. Dr. Aaroe holds Texas license T2298.

Dr. Aaroe's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Aaroe's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Aaroe practices. Vendor and product names are available with a free account.

Neurology is Dr. Aaroe's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Aaroe is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Aaroe's licenses on file in 11 states: Texas, Florida, Arizona, Georgia, Oklahoma, Alabama, Louisiana, Mississippi, Tennessee, Washington and Minnesota.

Dmand AI lists acute mini-stroke (TIA), epilepsy, lower back pain, muscle pain, fibromyalgia, and limb pain and neuropathy among the conditions Dr. Aaroe treats.

CMS data shows 307 Medicare services from Dr. Aaroe across 8 procedure codes in 2024, for 191 Medicare patients. Medicare paid $27,409 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 191 Medicare patients who saw Dr. Aaroe in 2024. The largest group is 65 to 74, with 98 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.66, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Aaroe's median patient age at 69, with 55% women.

In 2024, Dr. Aaroe wrote 115 Medicare Part D claims for 45 patients. 95% of them were for generic drugs. CMS names the drug for 66 of them, across 4 drugs with 11 or more claims each, at $2,369 in total drug cost. In 2023, CMS named 17 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Aaroe for performance year 2024, reported as part of a group. Dr. Aaroe accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Aaroe as offering telehealth.

Dmand AI links 10 papers to Dr. Aaroe, published from 2019 to 2024. 2019 was the busiest year, with 2. The most frequent topics are Comorbidity, COVID-19 and Immunotherapy. Dr. Aaroe has published most often in Neurology. Dr. Aaroe's most frequent co-authors are Nazanin K. Majd, MD, Monica E. Loghin, MD and Barbara Jane O'Brien, MD.

CMS Open Payments shows 9 general payments to Dr. Aaroe from 1 drug or device company in 2025. Consulting fees make up the largest share, 93% of the total. Astellas Pharma Global Development paid the most, $12,901.

Dmand AI lists 2 awards for Dr. Aaroe, most recently Future Leaders Program Participant in 2024.

Dr. Aaroe graduated from Feinberg School of Medicine in 2015. Dr. Aaroe is a member of AAN and Society for Neuro-Oncology.

Dr. Aaroe is in network with 3 carriers, including Aetna, Blue Cross Blue Shield of Michigan and CMS Medicare. HMO plans come from the most carriers, 2. Check the plan with the practice before a visit.